Comparative Pharmacology
Head-to-head clinical analysis: BRISTAMYCIN versus E E S 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAMYCIN versus E E S 200.
BRISTAMYCIN vs E.E.S. 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BRISTAMYCIN is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
500 mg intravenously every 6 hours. Infuse over 60 minutes.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
None Documented
None Documented
Terminal elimination half-life: 6–8 hours (prolonged to 20–40 hours in severe renal impairment; dose adjustment required for CrCl <30 mL/min).
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5% as unchanged drug and metabolites.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic